Compugen Financials

CGEN Stock

USD 1.64 0.01 0.61%

Based on the analysis of Compugen's profitability, liquidity, and operating efficiency, Compugen may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Compugen's Common Stock Shares Outstanding is very stable compared to the past year. As of the 16th of February 2026, Non Current Liabilities Total is likely to grow to about 48.2 M, while Total Assets are likely to drop about 72.9 M.

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Compugen Balance Sheet Chart

At this time, Compugen's Common Stock Shares Outstanding is very stable compared to the past year. As of the 16th of February 2026, Non Current Liabilities Total is likely to grow to about 48.2 M, while Total Assets are likely to drop about 72.9 M.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity

Key indicators impacting Compugen's financial strength include:

Current Value

Last Year

Change From Last Year

10 Year Trend

Debt Equity Ratio

0.0448

0.061

Way Down

Slightly volatile

Current Ratio

9.97

6.05

Way Up

Slightly volatile

Investors should never underestimate Compugen's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to research Compugen's cash flow, debt, and profitability to make informed and accurate decisions about investing in Compugen.

Net Income

(13.45 Million)

Build AI portfolio with Compugen Stock

Understanding current and past Compugen Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Compugen's financial statements are interrelated, with each one affecting the others. For example, an increase in Compugen's assets may result in an increase in income on the income statement.

Compugen Stock Summary

Compugen competes with Innate Pharma, Nuvectis Pharma, Molecular Partners, Milestone Pharmaceuticals, and Rani Therapeutics. Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. Compugen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.

Specialization	Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Instrument	USA Stock View All
Exchange	NASDAQ Exchange
ISIN	IL0010852080
Business Address	Azrieli Center, Holon,
Sector	Life Sciences Tools & Services
Industry	Health Care
Benchmark	Dow Jones Industrial
Website	cgen.com
Phone	972 3 765 8585
Currency	USD - US Dollar

Compugen Key Financial Ratios

	Return On Equity	-0.53
	Operating Margin	(4.17) %
	Price To Sales	22.50 X
	Revenue	27.86 M
	Gross Profit	513 K

More Fundamentals

Compugen Key Balance Sheet Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	132.2M	94.2M	121.3M	115.0M	132.2M	72.9M
Other Current Liab	11.7M	9.5M	11.0M	8.2M	9.5M	10.0M
Net Debt	(5.1M)	(9.1M)	(12.5M)	(15.3M)	(13.8M)	(14.5M)
Retained Earnings	(422.1M)	(455.8M)	(474.5M)	(488.8M)	(439.9M)	(417.9M)
Accounts Payable	4.6M	1.8M	3.5M	1.8M	2.1M	1.9M
Cash	7.8M	11.1M	13.9M	18.2M	21.0M	24.8M
Net Receivables	188K	317K	61.3M	269K	309.4K	293.9K
Inventory	(780K)	(119.3M)	(6.0M)	(72.6M)	(65.4M)	(62.1M)
Total Liab	25.5M	16.5M	55.8M	60.1M	69.1M	72.5M
Total Current Assets	123.2M	86.1M	114.6M	106.0M	121.9M	128.0M
Common Stock	239K	240K	247K	248K	285.2K	299.5K
Other Liab	5.6M	5.5M	6.4M	3.3M	3.8M	4.6M
Other Assets	3.2M	4.7M	5.0M	4.7M	5.4M	5.7M
Other Current Assets	6.0M	2.5M	2.6M	2.5M	2.2M	2.9M
Short Term Debt	768K	613K	632K	448K	403.2K	802.3K
Net Tangible Assets	38.3M	119.8M	106.7M	77.7M	89.3M	77.0M
Net Invested Capital	106.7M	77.7M	65.6M	54.9M	63.2M	72.8M
Net Working Capital	106.1M	74.2M	88.3M	85.8M	98.7M	78.8M
Capital Stock	239K	240K	247K	248K	285.2K	244.5K

Compugen Key Income Statement Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Interest Expense	869K	27K	31K	34K	30.6K	29.1K
Total Revenue	6M	7.5M	33.5M	27.9M	32.0M	33.6M
Gross Profit	5.3M	6.5M	31.5M	19.9M	22.9M	24.1M
Operating Income	(35.1M)	(35.4M)	(13.0M)	(14.9M)	(13.4M)	(14.1M)
Ebit	(35.1M)	(35.4M)	(13.0M)	(14.9M)	(13.4M)	(14.1M)
Research Development	28.7M	30.6M	34.5M	24.8M	28.5M	18.3M
Ebitda	(34.6M)	(34.9M)	(12.5M)	(14.4M)	(13.0M)	(13.6M)
Cost Of Revenue	680K	975K	2.0M	7.9M	9.1M	9.6M
Income Before Tax	(34.2M)	(33.6M)	(9.8M)	(9.7M)	(8.7M)	(9.2M)
Net Income	(32.9M)	(33.7M)	(18.8M)	(14.2M)	(12.8M)	(13.4M)
Income Tax Expense	(1.3M)	58K	9.0M	4.5M	5.2M	5.5M
Interest Income	894K	1.7M	3.0M	3.5M	4.0M	4.2M
Net Interest Income	871K	1.7M	3.2M	5.2M	6.0M	6.3M

Compugen Key Cash Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Change In Cash	704K	2.9M	2.8M	4.0M	4.6M	4.8M
Free Cash Flow	(23.0M)	(35.0M)	(36.1M)	49.5M	44.5M	46.8M
Depreciation	461K	482K	476K	486K	437.4K	415.5K
Other Non Cash Items	(573K)	515K	(452K)	(1.7M)	(1.6M)	(1.5M)
Capital Expenditures	292K	487K	172K	118K	106.2K	100.9K
Net Income	(34.2M)	(33.7M)	(18.8M)	(14.2M)	(12.8M)	(13.4M)
End Period Cash Flow	8.5M	11.4M	14.3M	18.2M	16.4M	11.1M
Investments	6.9M	37.1M	35.5M	(46.3M)	(53.2M)	(50.5M)
Change To Netincome	2.3M	2.9M	4.2M	4.3M	4.9M	2.9M

Compugen Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Compugen's current stock value. Our valuation model uses many indicators to compare Compugen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Compugen competition to find correlations between indicators driving Compugen's intrinsic value. More Info.

Compugen is rated second in return on equity category among its peers. It is number one stock in return on asset category among its peers . At this time, Compugen's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Compugen's earnings, one of the primary drivers of an investment's value.

Most indicators from Compugen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Compugen current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued.

To learn how to invest in Compugen Stock, please use our How to Invest in Compugen guide.At this time, Compugen's Tax Provision is very stable compared to the past year. As of the 16th of February 2026, Enterprise Value is likely to grow to about 146.1 M, while Selling General Administrative is likely to drop about 6.8 M.

	2023	2024	2025	2026 (projected)
Net Interest Income	3.2M	5.2M	6.0M	6.3M
Interest Income	3.0M	3.5M	4.0M	4.2M

Net Interest Income Interest Income

Compugen fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Other Liab	Current Deferred Revenue	Other Assets	Short Term Investments
Total Assets		0.77	0.67	0.88	0.36	0.01	-0.7	0.42	0.04	0.37	-0.02	0.83	0.28	0.74	0.73	0.36	-0.61	0.75	0.48	0.5	0.91	0.73	-0.26	0.27	0.71	0.64
Other Current Liab	0.77		0.89	0.58	0.26	0.42	-0.9	0.6	-0.36	0.01	0.29	0.77	0.33	0.93	0.93	0.56	-0.69	0.92	0.7	0.64	0.88	0.93	-0.25	0.46	0.96	0.84
Total Current Liabilities	0.67	0.89		0.35	0.13	0.32	-0.82	0.52	-0.25	0.01	0.22	0.68	0.46	0.86	0.9	0.83	-0.63	0.87	0.92	0.81	0.83	0.88	-0.19	0.76	0.89	0.67
Total Stockholder Equity	0.88	0.58	0.35		0.44	-0.18	-0.46	0.34	0.21	0.52	-0.14	0.76	0.1	0.55	0.51	-0.01	-0.43	0.56	0.12	0.24	0.77	0.52	-0.3	-0.11	0.5	0.51
Property Plant And Equipment Net	0.36	0.26	0.13	0.44		-0.26	-0.34	0.32	0.3	0.06	-0.27	0.39	-0.1	0.35	0.32	-0.08	-0.04	0.37	-0.01	0.49	0.34	0.33	-0.52	-0.35	0.28	0.28
Net Debt	0.01	0.42	0.32	-0.18	-0.26		-0.35	0.08	-0.99	-0.43	0.62	0.1	0.08	0.34	0.36	0.33	-0.5	0.29	0.34	0.12	0.14	0.35	0.05	0.35	0.44	0.52
Retained Earnings	-0.7	-0.9	-0.82	-0.46	-0.34	-0.35		-0.47	0.29	-0.01	-0.28	-0.69	-0.29	-0.95	-0.94	-0.58	0.66	-0.95	-0.69	-0.67	-0.77	-0.95	0.17	-0.43	-0.93	-0.73
Accounts Payable	0.42	0.6	0.52	0.34	0.32	0.08	-0.47		-0.07	0.0	0.09	0.28	0.35	0.41	0.41	0.08	-0.05	0.44	0.24	0.31	0.41	0.41	-0.35	0.06	0.48	0.31
Cash	0.04	-0.36	-0.25	0.21	0.3	-0.99	0.29	-0.07		0.45	-0.62	-0.02	-0.09	-0.26	-0.28	-0.25	0.46	-0.21	-0.26	-0.03	-0.07	-0.27	-0.06	-0.29	-0.36	-0.46
Non Current Assets Total	0.37	0.01	0.01	0.52	0.06	-0.43	-0.01	0.0	0.45		0.07	0.23	-0.08	0.09	0.06	-0.1	0.06	0.11	-0.07	0.01	0.19	0.07	-0.31	-0.11	-0.03	-0.09
Non Currrent Assets Other	-0.02	0.29	0.22	-0.14	-0.27	0.62	-0.28	0.09	-0.62	0.07		0.01	-0.04	0.25	0.25	0.22	-0.28	0.23	0.22	0.04	0.0	0.26	-0.04	0.23	0.31	0.4
Cash And Short Term Investments	0.83	0.77	0.68	0.76	0.39	0.1	-0.69	0.28	-0.02	0.23	0.01		-0.11	0.83	0.83	0.53	-0.62	0.83	0.6	0.63	0.93	0.82	-0.16	0.33	0.82	0.84
Net Receivables	0.28	0.33	0.46	0.1	-0.1	0.08	-0.29	0.35	-0.09	-0.08	-0.04	-0.11		0.2	0.21	0.21	-0.28	0.21	0.31	0.23	0.27	0.21	-0.15	0.39	0.2	-0.09
Common Stock Total Equity	0.74	0.93	0.86	0.55	0.35	0.34	-0.95	0.41	-0.26	0.09	0.25	0.83	0.2		0.99	0.66	-0.7	1.0	0.76	0.74	0.88	1.0	-0.18	0.49	0.98	0.82
Common Stock Shares Outstanding	0.73	0.93	0.9	0.51	0.32	0.36	-0.94	0.41	-0.28	0.06	0.25	0.83	0.21	0.99		0.72	-0.72	0.99	0.81	0.79	0.88	1.0	-0.22	0.56	0.98	0.82
Non Current Liabilities Total	0.36	0.56	0.83	-0.01	-0.08	0.33	-0.58	0.08	-0.25	-0.1	0.22	0.53	0.21	0.66	0.72		-0.54	0.67	0.98	0.8	0.59	0.7	0.02	0.93	0.68	0.52
Inventory	-0.61	-0.69	-0.63	-0.43	-0.04	-0.5	0.66	-0.05	0.46	0.06	-0.28	-0.62	-0.28	-0.7	-0.72	-0.54		-0.69	-0.59	-0.5	-0.71	-0.71	0.2	-0.43	-0.73	-0.72
Other Stockholder Equity	0.75	0.92	0.87	0.56	0.37	0.29	-0.95	0.44	-0.21	0.11	0.23	0.83	0.21	1.0	0.99	0.67	-0.69		0.77	0.77	0.88	1.0	-0.23	0.5	0.97	0.8
Total Liab	0.48	0.7	0.92	0.12	-0.01	0.34	-0.69	0.24	-0.26	-0.07	0.22	0.6	0.31	0.76	0.81	0.98	-0.59	0.77		0.84	0.7	0.79	-0.05	0.9	0.78	0.6
Property Plant And Equipment Gross	0.5	0.64	0.81	0.24	0.49	0.12	-0.67	0.31	-0.03	0.01	0.04	0.63	0.23	0.74	0.79	0.8	-0.5	0.77	0.84		0.69	0.77	-0.44	0.61	0.72	0.57
Total Current Assets	0.91	0.88	0.83	0.77	0.34	0.14	-0.77	0.41	-0.07	0.19	0.0	0.93	0.27	0.88	0.88	0.59	-0.71	0.88	0.7	0.69		0.88	-0.21	0.47	0.87	0.79
Common Stock	0.73	0.93	0.88	0.52	0.33	0.35	-0.95	0.41	-0.27	0.07	0.26	0.82	0.21	1.0	1.0	0.7	-0.71	1.0	0.79	0.77	0.88		-0.19	0.53	0.98	0.82
Other Liab	-0.26	-0.25	-0.19	-0.3	-0.52	0.05	0.17	-0.35	-0.06	-0.31	-0.04	-0.16	-0.15	-0.18	-0.22	0.02	0.2	-0.23	-0.05	-0.44	-0.21	-0.19		0.12	-0.16	-0.16
Current Deferred Revenue	0.27	0.46	0.76	-0.11	-0.35	0.35	-0.43	0.06	-0.29	-0.11	0.23	0.33	0.39	0.49	0.56	0.93	-0.43	0.5	0.9	0.61	0.47	0.53	0.12		0.52	0.35
Other Assets	0.71	0.96	0.89	0.5	0.28	0.44	-0.93	0.48	-0.36	-0.03	0.31	0.82	0.2	0.98	0.98	0.68	-0.73	0.97	0.78	0.72	0.87	0.98	-0.16	0.52		0.87
Short Term Investments	0.64	0.84	0.67	0.51	0.28	0.52	-0.73	0.31	-0.46	-0.09	0.4	0.84	-0.09	0.82	0.82	0.52	-0.72	0.8	0.6	0.57	0.79	0.82	-0.16	0.35	0.87

Click cells to compare fundamentals

Compugen Account Relationship Matchups

Compugen fundamental ratios Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	132.2M	94.2M	121.3M	115.0M	132.2M	72.9M
Other Current Liab	11.7M	9.5M	11.0M	8.2M	9.5M	10.0M
Net Debt	(5.1M)	(9.1M)	(12.5M)	(15.3M)	(13.8M)	(14.5M)
Retained Earnings	(422.1M)	(455.8M)	(474.5M)	(488.8M)	(439.9M)	(417.9M)
Accounts Payable	4.6M	1.8M	3.5M	1.8M	2.1M	1.9M
Cash	7.8M	11.1M	13.9M	18.2M	21.0M	24.8M
Net Receivables	188K	317K	61.3M	269K	309.4K	293.9K
Inventory	(780K)	(119.3M)	(6.0M)	(72.6M)	(65.4M)	(62.1M)
Total Liab	25.5M	16.5M	55.8M	60.1M	69.1M	72.5M
Total Current Assets	123.2M	86.1M	114.6M	106.0M	121.9M	128.0M
Common Stock	239K	240K	247K	248K	285.2K	299.5K
Other Liab	5.6M	5.5M	6.4M	3.3M	3.8M	4.6M
Other Assets	3.2M	4.7M	5.0M	4.7M	5.4M	5.7M
Other Current Assets	6.0M	2.5M	2.6M	2.5M	2.2M	2.9M
Short Term Debt	768K	613K	632K	448K	403.2K	802.3K
Net Tangible Assets	38.3M	119.8M	106.7M	77.7M	89.3M	77.0M
Net Invested Capital	106.7M	77.7M	65.6M	54.9M	63.2M	72.8M
Net Working Capital	106.1M	74.2M	88.3M	85.8M	98.7M	78.8M
Capital Stock	239K	240K	247K	248K	285.2K	244.5K

Today, most investors in Compugen Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Compugen's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Compugen growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.49

At this time, Compugen's Price Earnings To Growth Ratio is very stable compared to the past year.

Compugen February 16, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Compugen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Compugen. We use our internally-developed statistical techniques to arrive at the intrinsic value of Compugen based on widely used predictive technical indicators. In general, we focus on analyzing Compugen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Compugen's daily price indicators and compare them against related drivers.

	Downside Deviation	3.49
	Information Ratio	(0)
	Maximum Drawdown	23.25
	Value At Risk	(5.00)
	Potential Upside	6.57

When determining whether Compugen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Compugen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Compugen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Compugen Stock:

How To Invest In Compugen

Details

Is Compugen Stock a good investment?

Details

What is Compugen's Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in discontinued.

To learn how to invest in Compugen Stock, please use our How to Invest in Compugen guide.

You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Will Life Sciences Tools & Services sector continue expanding? Could Compugen diversify its offerings? Factors like these will boost the valuation of Compugen. Projected growth potential of Compugen fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Compugen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Earnings Share

(0.30)

Revenue Per Share

0.075

Quarterly Revenue Growth

(0.89)

Return On Assets

(0.18)

Return On Equity

(0.53)

Investors evaluate Compugen using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Compugen's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Compugen's market price to deviate significantly from intrinsic value.

It's important to distinguish between Compugen's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Compugen should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Compugen's market price signifies the transaction level at which participants voluntarily complete trades.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Compugen Financials

Compugen Balance Sheet Chart

Net Income

(13.45 Million)

Compugen Stock Summary

Compugen Key Financial Ratios

Compugen Key Balance Sheet Accounts

Compugen Key Income Statement Accounts

Compugen Key Cash Accounts

Compugen Financial Ratios Relationships

Compugen fundamental ratios Correlations

Compugen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Compugen fundamental ratios Accounts

Price Earnings To Growth Ratio

0.49

Compugen February 16, 2026 Opportunity Range

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Stockholder Equity	+ 1.0	Common Stock Total Equity
Common Stock	+ 1.0	Common Stock Total Equity
Common Stock	+ 1.0	Common Stock Shares Outstanding
Common Stock	+ 1.0	Other Stockholder Equity
Common Stock Shares Outstanding	+ 0.99	Common Stock Total Equity
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding

Cash	- 0.99	Net Debt
Common Stock	- 0.95	Retained Earnings
Other Stockholder Equity	- 0.95	Retained Earnings
Common Stock Total Equity	- 0.95	Retained Earnings
Common Stock Shares Outstanding	- 0.94	Retained Earnings
Other Assets	- 0.93	Retained Earnings